# US 2026/0062423 A1 · Biologically active molecules, conjugates thereof, and therapeutic uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0062423 A1
- Document ID: US20260062423A1
- Status: Published application
- Kind: A1
- Application number: 19/255,790
- Filed: 2025-06-30
- Published: 2026-03-05
- Earliest claimed: 2013-03-15
- Assignees: Regeneron Pharmaceuticals, Inc.
- Applicants: Regeneron Pharmaceuticals, Inc.
- Inventors: Thomas NITTOLI
- Web page: https://patentgrep.com/patent/US20260062423A1

## CPC

- C07D 507/00: Heterocyclic compounds containing a condensed beta-lactam ring system, not provided for by groups C07D463/00, C07D477/00 or C07D499/00 - C07D505/00; Such ring systems being further condensed
- A61K 31/5365: ortho- or peri-condensed with heterocyclic ring systems
- A61K 47/68033: {the drug being a maytansine}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6855: {the tumour determinant being from breast cancer cell}
- A61K 47/6869: {the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate}
- A61K 47/6871: {the antibody targeting an enzyme}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to linker compounds that are useful in covalently linking biologically active molecules with Ligands. The disclosed compounds also relate to biologically active molecules and Ligand conjugates, wherein the biologically active molecule is linked to the Ligand through a linker. The disclosure further provides compositions comprising biologically active molecule-ligand conjugates, methods of modifying abnormal cell growth and methods of treatment using the conjugates or the compositions.

## Claims

### Claim at position 1

-47. (canceled)

### Claim 48

A method of killing a cell, comprising contacting the cell with a composition in an amount sufficient to kill the cell, wherein the cell is killed, wherein the composition comprises a compound, and wherein the compound has the following formula:
or a pharmaceutically acceptable salt thereof, or an antibody conjugate thereof,
wherein A3a is —CH2—, —CH2CH2—, or —CH2CH2CH2CH2—; and
R4a is a substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl.

### Claim 49 (depends on 48)

The method of claim 48, wherein A3a is —CH2CH2—.

### Claim 50 (depends on 48)

The method of claim 48, wherein R4a is a substituted or unsubstituted alkyl.

### Claim 51 (depends on 48)

The method of claim 48, wherein the compound is

### Claim 52 (depends on 48)

The method of claim 48, wherein the cell is a tumor cell.

### Claim 53 (depends on 52)

The method of claim 52, wherein the tumor cell is a prostate cancer cell.

### Claim 54 (depends on 52)

The method of claim 52, wherein the tumor cell is a breast cancer cell.

### Claim 55 (depends on 52)

The method of claim 52, wherein the tumor cell is a glioblastoma cancer cell.

### Claim 56 (depends on 48)

The method of claim 48, wherein the composition comprises an antibody-drug conjugate (ADC) comprising the following formula:
or a pharmaceutically acceptable salt thereof,
wherein:
Ab is an antibody or antigen-binding fragment thereof;
AA2AA1 is a peptide residue selected from the group consisting of valine-citrulline, citrulline-valine, lysine-phenylalanine, phenylalanine-lysine, valine-asparagine, asparagine-valine, threonine-asparagine, serine-asparagine, asparagine-serine, phenylalanine-asparagine, asparagine-phenylalanine, leucine-asparagine, asparagine-leucine, isoleucine-asparagine, asparagine-isoleucine, glycine-asparagine, asparagine-glycine, glutamic acid-asparagine, asparagine-glutamic acid, citrulline-asparagine, asparagine-citrulline, alanine-asparagine, and asparagine-alanine residues;
a is an integer from 1 to 10;
q is 0 or an integer from 1 to 5;
A3 is —CH2—, —CH2CH2—, or —CH2CH2CH2CH2—;
R4a is a substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl;
R17 is selected from the group consisting of O, S, NR18, CR5R6;
R1 is an amino acid residue, a peptide residue having 2-20 amino acid residues, an alkyl, an alkynyl, an alkenyl, a cycloalkyl, an aryl, a heteroaryl, a heterocyclyl, —CR5R6—, —O—, —C(═O)—, —O—C(═O)—, —C(═O)—O—, —O—C(═O)—O—, —C(═O)—(CHx)p1—, —C(═O)—O—(CHx)p1—, —(CHx)p1—C(═O)—, —(CHx)p1—C(═O)—O—, —(O—(CH2)p2—)p3—, —((CH2)p2—O—)p3—, —C(═S)—, —C(═S)—S—, —C(═S)—NH—, —S—C(═S)—, —S—C(═S)—S—, —S—, —SO—, —SO2—, —NR4—, —N(R4)—C(═O)—N(R8)—, —N(R4)—C(═O)O—, —N(R4)—C(═O)—, —C(═O)—N(R4)—, —C(═O)—N(R4)—C(═O)—, —O—C(═O)—NR4—, wherein alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted;
R4, R5, R6 and R5 are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl;
R9, R10, R11, and R12 are each independently H, halogen, NR13R14, nitro, cyano, —OH, —O—C(═O)—R15, —C(═O)—R15, —C(═O)—O—R15, —C(═O)—NR13R14, substituted or unsubstituted: alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl; and
R13 and R14 are each independently H or an optionally substituted alkyl; and R15 is an optionally substituted alkyl.

### Claim 57 (depends on 56)

The method of claim 56, wherein the ADC is
or a pharmaceutically acceptable salt thereof,
wherein:
Ab is an antibody or antigen-binding fragment thereof; and
a is an integer from 1 to 10.

### Claim 58

A method of treatment of a medical disorder in an individual suffering from the medical disorder, comprising administering to the individual an effective amount of a composition comprising a compound, wherein the compound has the following formula:
or a pharmaceutically acceptable salt thereof, or an antibody conjugate thereof,
wherein A3a is —CH2—, —CH2CH2—, or —CH2CH2CH2CH2—; and
R4a is a substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl.

### Claim 59 (depends on 58)

The method of claim 58, wherein A3a is —CH2CH2—.

### Claim 60 (depends on 58)

The method of claim 58, wherein R4a is a substituted or unsubstituted alkyl.

### Claim 61 (depends on 58)

The method of claim 58, wherein the compound is
or a pharmaceutically acceptable salt thereof.

### Claim 62 (depends on 58)

The method of claim 58, wherein the composition comprises an ADC comprising the following formula:
wherein:
Ab is an antibody or antigen-binding fragment thereof;
AA2AA1 is a peptide residue selected from the group consisting of valine-citrulline, citrulline-valine, lysine-phenylalanine, phenylalanine-lysine, valine-asparagine, asparagine-valine, threonine-asparagine, serine-asparagine, asparagine-serine, phenylalanine-asparagine, asparagine-phenylalanine, leucine-asparagine, asparagine-leucine, isoleucine-asparagine, asparagine-isoleucine, glycine-asparagine, asparagine-glycine, glutamic acid-asparagine, asparagine-glutamic acid, citrulline-asparagine, asparagine-citrulline, alanine-asparagine, and asparagine-alanine residues;
a is an integer from 1 to 10;
q is 0 or an integer from 1 to 5;
A3 is —CH2—, —CH2CH2—, or —CH2CH2CH2CH2—;
R4a is a substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl;
R17 is selected from the group consisting of O, S, NR18, CR5R6;
R1 is an amino acid residue, a peptide residue having 2-20 amino acid residues, an alkyl, an alkynyl, an alkenyl, a cycloalkyl, an aryl, a heteroaryl, a heterocyclyl, —CR5R6—, —O—, —C(═O)—, —O—C(═O)—, —C(═O)—O—, —O—C(═O)—O—, —C(═O)—(CHx)p1—, —C(═O)—O—(CHx)p1—, —(CHx)p1—C(═O)—, —(CHx)p1—C(═O)—O—, —(O—(CH2)p2—)p3—, —((CH2)p2—O—)p3—, —C(═S)—, —C(═S)—S—, —C(═S)—NH—, —S—C(═S)—, —S—C(═S)—S—, —S—, —SO—, —SO2—, —NR4—, —N(R4)—C(═O)—N(R8)—, —N(R4)—C(═O)O—, —N(R4)—C(═O)—, —C(═O)—N(R4)—, —C(═O)—N(R4)—C(═O)—, —O—C(═O)—NR4—, wherein alkyl, alkynyl, alkenyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted;
R4, R5, R6 and R5 are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl;
R9, R10, R11, and R12 are each independently H, halogen, NR13R14, nitro, cyano, —OH, —O—C(═O)—R15, —C(═O)—R15, —C(═O)—O—R15, —C(═O)—NR13R14, substituted or unsubstituted: alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl; and
R13 and R14 are each independently H or an optionally substituted alkyl; and R15 is an optionally substituted alkyl.

### Claim 63 (depends on 62)

The method of claim 62, wherein the ADC is
or a pharmaceutically acceptable salt thereof,
wherein:
Ab is an antibody or antigen-binding fragment thereof; and
a is an integer from 1 to 10.

### Claim 64 (depends on 58)

The method of claim 58, wherein the individual is a mammal.

### Claim 65 (depends on 58)

The method of claim 58, further comprising administering sequentially or consecutively an additional therapy.

### Claim 66 (depends on 65)

The method of claim 65, wherein the additional therapy is radiation therapy, chemotherapy, or a combination of both.

### Claim 67 (depends on 58)

The method of claim 58, further comprising administering at least one additional therapeutic agent.

### Claim 68 (depends on 58)

The method of claim 58, wherein the medical disorder is selected from the group consisting of tumors, cancers, infectious diseases, neurodegenerative diseases, bone disorders, and cardiovascular diseases.
